Clinical Significance and Prognostic Value of Pentraxin-3 as Serologic Biomarker for Lung Cancer |
Zhang, Dai
(Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Ren, Wei-Hong (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine) Gao, Yun (Center of Clinical Laboratory, Henan Province Tumour Hospital) Wang, Nian-Yue (Department of Clinical Laboratory, the Second Affiliated Hospital of Southeast University) Wu, Wen-Jun (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
1 | Alessandro R, Fontana S, Kohn E, De Leo G (2005). Proteomic strategies and their application in cancer research. Tumori, 9, 447-55. |
2 | Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer. J Clin Oncol, 27, 2217-24. DOI ScienceOn |
3 | Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45 DOI ScienceOn |
4 | Banks R, Selby P (2003). Clinical proteomics-insights into pathologies and benefits for patients. Lancet, 362, 415-6. DOI ScienceOn |
5 | Deban L, Jaillon S, Garlanda C, et al (2010). Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res, 343, 237-49. |
6 | Diamandis EP, Goodglick L, Planque C, et al (2011). Pentraxin-3 is a novel biomarker of lung Carcinoma. Clin Cancer Res, 17, 2395-99. DOI |
7 | Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI ScienceOn |
8 | Garlanda C, Bottazzi B, Bastone A, et al (2005). Pentraxins at the crossroads between innate mmunity,inflammation, matrix deposition, and female fertility. Annu Rev Immunol, 23, 337-66. DOI ScienceOn |
9 | Groome PA, Bolejack V, Cruwley JJ, et a1 (2007).The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705. DOI |
10 | Hassanein M, Callison JC, Callaway-Lane C, et al (2012). The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res, 5, 992-1006. DOI |
11 | IARC Working Group (1997). IARC handbook of cancer prevention, volume 1: non-steroidal anti-inflammatory drugs. Lyon (France): IARC-WHO. |
12 | Jackson JR, Seed MP, Kircher CH, et al (1997). The codependence of angiogenesis and chronic inflammation. FASEB J, 11, 457-65. |
13 | Jaiswal M, LaRusso NF, Burgart LJ, et al (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res, 60, 184-90. |
14 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
15 | Keller A, Leidinger P, Gislefoss R, et a1(201l). STable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol, 8, 506-16. DOI |
16 | Kulasingam V, Diamandis EP (2008). Strategies for discovering novelcancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol, 5, 588-99. DOI ScienceOn |
17 | Kuper H, Adami HO, Trichopoulos D (2000). Infections as a major prevenTable cause of human cancer. J Intern Med, 248, 171-83. DOI ScienceOn |
18 | Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 19, 860-67 |
19 | Locker GY, Hamilton S, Harris J, et al (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24, 5313-27. DOI ScienceOn |
20 | Locatelli M, Ferrero S, Martinelli Boneschi F, et al.The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas(2013). J Neuroimmunol, 260, 99-106 |
21 | Martini N,Baills MS, Burt ME, et a1(1995). Incidence of local recurrence and second primaries in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109, 120-9. DOI ScienceOn |
22 | McWilliams A, Lmn B, Sutedja T (2009). Early proximal lung cancer diagnosis and treatment. Eur Respir J, 33, 656-65. DOI ScienceOn |
23 | Okutani D (2006). The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi, 29, 107-13. DOI ScienceOn |
24 | Pepe MS, Etzioni R, Feng Z, et al (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst, 93, 1054-61. DOI ScienceOn |
25 | Planque C, Kulasingam V, Smith CR, et al (2009). Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics, 8, 2746-58. DOI ScienceOn |
26 | Pujol JL, Grenier J, Daures JP, et al (1993). Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res, 53, 61-6. |
27 | Rabman SM, Gonzalez AL, Li M, et a1 (2011). Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res, 71, 3009-17. DOI ScienceOn |
28 | Ravenna L, Sale P, Di Vito M, et al (2009). Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. The Prostate, 69, 1245-55. DOI ScienceOn |
29 | Sehramm M, Wrobel C, Born I, et al (2011). Equivocal cytology in lung cancer diagnosis: improvement of diagnostic accuracy using adjuvant multicolor FISH, DNA-image cytometry, and quantitative promoter hypermethylation analysis. Cancer Cytopathol, 119, 177-92. DOI |
30 | Reed MF, Molloy M, Dalton EL, et al (2004). Survival after resection for lung cancer is the outcome that matters. Am J Surg, 188, 598-602. DOI ScienceOn |
31 | Shinkai T, Saijo N, Tominaga K, et al (1986). Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer, 57, 1318-23. DOI |
32 | Spiro SG, Gould MK, Colice GL,et al (2007). Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132, S149-60. DOI ScienceOn |
33 | Wagner PD, Verma M, Srivastava S (2004). Challenges for biomarkers in cancer detection. Ann N Y Acad Sci, 1022, 9-16. DOI ScienceOn |
34 | Willeke F, Assad A, Findeisen P, et al (2005). Overexpression of a member of the pentraxins family (PTX3) in human soft tissue liposarcoma. Eur J Cancer, 42, 2639-46. |
![]() |